[go: up one dir, main page]

MX2022010781A - Vacuna contra el virus sars-cov-2 con adyuvante cpg. - Google Patents

Vacuna contra el virus sars-cov-2 con adyuvante cpg.

Info

Publication number
MX2022010781A
MX2022010781A MX2022010781A MX2022010781A MX2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A MX 2022010781 A MX2022010781 A MX 2022010781A
Authority
MX
Mexico
Prior art keywords
cov
sars
virus
vaccine against
cpg adjuvant
Prior art date
Application number
MX2022010781A
Other languages
English (en)
Inventor
Robert Schlegl
Christoph Reinisch
Robert S Janssen
Andreas Meinke
Jürgen Heindl-Wruss
John D Campbell
David Novack
Michael Möhlen
Christian Taucher
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Priority claimed from PCT/IB2021/052858 external-priority patent/WO2021176434A1/en
Publication of MX2022010781A publication Critical patent/MX2022010781A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Aquí se describen vacunas contra el SARS-CoV-2 con adyuvante CpG y composiciones y métodos para producir y administrar dichas vacunas a sujetos que las necesitan.
MX2022010781A 2020-04-06 2021-04-06 Vacuna contra el virus sars-cov-2 con adyuvante cpg. MX2022010781A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202124 2020-10-15
EP20211936 2020-12-04
EP21154645 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160933 2021-03-05
PCT/IB2021/052858 WO2021176434A1 (en) 2020-03-01 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine

Publications (1)

Publication Number Publication Date
MX2022010781A true MX2022010781A (es) 2023-03-09

Family

ID=83887208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010781A MX2022010781A (es) 2020-04-06 2021-04-06 Vacuna contra el virus sars-cov-2 con adyuvante cpg.

Country Status (5)

Country Link
KR (1) KR20230005814A (es)
CN (1) CN115666633A (es)
CA (1) CA3168783A1 (es)
MX (1) MX2022010781A (es)
PH (1) PH12022552300A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114432437A (zh) * 2022-01-07 2022-05-06 广东粤港澳大湾区国家纳米科技创新研究院 四氧化三锰颗粒在制备疫苗佐剂中的应用
CN116983401B (zh) * 2023-06-29 2025-03-07 贝湾生物科技有限公司 基于sars1病毒的新冠加强免疫疫苗

Also Published As

Publication number Publication date
KR20230005814A (ko) 2023-01-10
CA3168783A1 (en) 2021-09-10
PH12022552300A1 (en) 2023-12-11
CN115666633A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
WO2021204825A3 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
EP4218807A3 (en) Zika virus vaccine
MX2018014573A (es) Vacuna contra el virus del zika.
MX2021001762A (es) Metodo y composicion para estimular la respuesta inmunitaria.
MX2024006606A (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
MX2017014538A (es) Regimenes de cebado-refuerzo que implican la administracion de al menos un constructo de arnm.
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
PE20151588A1 (es) Vacuna contra el virus del dengue
MX2020011712A (es) Vacunas de nanoparticulas multivalentes contra la influenza.
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
MX392862B (es) Formulación de vacuna contra el vih.
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CO2024007500A2 (es) Uso del interferón como adyuvante en vacunas
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
MX2022012447A (es) Vacuna inactivada contra el virus sars-cov-2.
CO2022016537A2 (es) Vacuna inactivada para sars-cov-2 y preparación de la misma
EA202190914A1 (ru) Иммуногенные композиции
BR112021017691A2 (pt) Formulações imunogênicas para o tratamento do câncer
BRPI0516314A (pt) uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso